Fundraising Fox

Curevo Vaccine

Founded 2017 · 43 employees on LinkedIn · 9 known investors

Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases. It operates in clinical-stage vaccine development.

BiotechHealthtech

Founders & leadership

GSGeorge Simeon
George SimeoninCEO
GS
Gregory S. CurhanCFO
GDGuy De La Rosa
Guy De La RosainCMO

Investors · 9

Adjuvant CapitalNew York · $10M – $25M
OrbiMedNew York · $1M – $75M
RA CapitalBoston
Sanofi VenturesCambridge · $5M
HBM Healthcare InvestmentsreportedZug
Janus Henderson InvestorsreportedNew York
Medicxireported · 2 sourcesLondon

Also in the syndicate · 2

GC BiopharmaHBM Healthcare Investors

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Curevo: $110 Million (Series B) Raised For Advancing Amezosvatein Shinglespulse2.com · Mar 2025Curevo Raises $110M for Shingles Vaccineclinicaltrialvanguard.com · Mar 2025Vaccine maker Curevo names Slaoui as chair, raises $110 millionstatnews.com · Mar 2025$60 Million Funding Supports Shingles Vaccine Candidate - Curevo Vaccinecurevovaccine.com · Feb 2022Vaccine startup Curevo takes on pharma giant GSK, raises $60M for trial of shingles shot - Curevo Vaccinecurevovaccine.com · Feb 2022News - Curevo Vaccinecurevovaccine.com · May 2021

Frequently asked questions

What does Curevo Vaccine do?
Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases. It operates in clinical-stage vaccine development.
Who are Curevo Vaccine's investors?
Curevo Vaccine's investors include Adjuvant Capital, OrbiMed, RA Capital, Sanofi Ventures, HBM Healthcare Investments, Janus Henderson Investors, Medicxi.